Antibiotic resistance is a major global health challenge and, worryingly, several key Gram
negative pathogens can become resistant to most currently available antibiotics. Polymyxins …

In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

The emergence of multidrug-resistant Gram-negative bacteria that cause nosocomial
infections is a growing problem worldwide. Colistin was first introduced in 1952 and was …

Increasing antibiotic resistance in Gram-negative bacteria, particularly in Pseudomonas
aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, presents a global …

Background: The superiority of combination therapy for carbapenem-resistant Gram-
negative bacilli (CR-GNB) remains controversial. In vitro models may predict the efficacy of …

Colistin has been re-introduced into clinical practice for the treatment of carbapenem-
resistant Gram-negative bacteria. Studies in the last decade attempted to reconstruct the …

Our objective was to examine the evidence of in vitro synergy of polymyxin-carbapenem
combination therapy against Gram-negative bacteria (GNB). A systematic review and meta …

The polymyxin antibiotics [colistin and polymyxin B (PMB)] are increasingly used as a last-
line option for the treatment of infections caused by extensively drug-resistant Gram …

The recent surge in multidrug-resistant pathogens combined with the diminishing antibiotic
pipeline has created a growing need to optimize the use of our existing antibiotic …

'Old'colistin and polymyxin B are increasingly used as last-line therapy against multidrug-
resistant Gram-negative bacteria Pseudomonas aeruginosa, Acinetobacter baumannii, and …